AbbVie (ABBV) Gross Profit (2012 - 2026)

AbbVie has disclosed Gross Profit across 15 years of filings, most recently posting $10.8 billion for Q1 2026.

• In Q1 2026, Gross Profit rose 15.45% year-over-year to $10.8 billion; the TTM figure through Mar 2026 stood at $44.4 billion (up 9.48% YoY), while the FY2025 annual figure was $43.0 billion, up 8.94% from the prior year.
• Gross Profit declined to $10.8 billion in Q1 2026, from $12.1 billion in the prior quarter.
• Over the last five years, Gross Profit for ABBV reached as high as $12.1 billion in Q4 2025 and fell as low as $7.4 billion in Q3 2023.
• The 5-year median for Gross Profit is $10.2 billion (2024), against an average of $9.9 billion.
• Annual changes were most pronounced in 2023 — Gross Profit dropped 23.98% — and 2024, when it soared 37.7%.
• A 5-year view of Gross Profit shows it stood at $11.0 billion in 2022, then declined by 21.5% to $8.6 billion in 2023, then grew by 24.53% to $10.7 billion in 2024, then gained by 12.7% to $12.1 billion in 2025, then dropped by 10.62% to $10.8 billion in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $10.8 billion, $12.1 billion, and $10.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.